Former Chief Medical Officer · DiaMedica Therapeutics Inc. (DMAC)

Kirsten Gruis

A named executive officer of DiaMedica Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$596,083

Salary $298,643Stock awards $0

FY2022: $1,004,691

3rd of 4 named executive officers at DiaMedica Therapeutics by FY2023 total.

4 named officers on file for DiaMedica Therapeutics, FY2023

Kirsten Gruis’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • DMAC’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how DiaMedica Therapeutics’s whole pay program stands against its peers

  • DiaMedica Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DMAC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2024 (DEF 14A).

Free

Get Kirsten Gruis’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kirsten Gruis compensation by year

DiaMedica Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as DiaMedica Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$364,167$298,643
Bonus$0$0
Stock awards$0$0
Option awards$487,789$146,790
Non-equity incentive$137,085$0
Pension and deferred compensation$0$0
All other$15,650$150,650
Total$1,004,691$596,083

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DiaMedica Therapeutics Inc. DEF 14A filed April 4, 2024, accession 0001437749-24-010985, and prior-year filings. Open the filing on EDGAR.

How this page was built: the DiaMedica Therapeutics Inc. filed document, accession 0001437749-24-010985. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.

$1.0M
$596K
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option67,000—$2.73
Option83,333—$3.88

Per the Outstanding Equity Awards at Fiscal Year-End table in DiaMedica Therapeutics Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

DiaMedica Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Rick PaulsPresident and Chief Executive Officer$1,215,161
Scott KellenChief Financial Officer and Secretary$632,215
Kirsten Gruis · this pageFormer Chief Medical Officer$596,083
Julie DavesSVP, Clinical Development Operations$533,370

The full DiaMedica Therapeutics compensation record

free company brief

This page is one person within DiaMedica Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the DiaMedica Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DiaMedica Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kirsten Gruis's compensation dossier · One-time report. No refunds.